Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. (Nasdaq: CRXT) is a specialty pharmaceutical company focused on men's health, best known for JATENZO, the first FDA-approved oral softgel testosterone replacement therapy. The company entered the public markets through a merger with Blue Water Acquisition Corp, a healthcare-focused SPAC, with the business combination closing in 2021. The 8-K filed June 9, 2022 represents one of several current reports submitted by the post-merger company during its tenure as a listed issuer. At the time of the filing, CRXT was an active Nasdaq-listed entity operating in the specialty pharma and men's health sector. Sign up at SpacDesk for full filing history, deal terms, and sponsor-level data on CRXT and hundreds of other SPAC transactions.